Technopath Clinical Diagnostics Expands Its Portfolio: Antibody Testing


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ technopath-clinical-diagnostics-expands-its-portfolio-antibody-testing
Company launches third-party quality control products enabling an independent, totally unbiased assessment of a diagnostic device or method for COVID-19 antibody testing.

Technopath Clinical Diagnostics today launched its Multichem ID-COVID-19 Quality Control Solutions offering laboratories third-party quality control products enabling an independent, totally unbiased assessment of a diagnostic device or method for COVID-19 antibody testing.

Multichem ID-Covid 19 Quality Controls
Triggered by a massive effort from the clinical diagnostic industry to introduce antibody tests worldwide, Technopath is responding to the urgent need from the laboratory community for third-party quality control solutions. Third-party is the term used to describe a laboratory control not purposefully designed or optimized for use with a specific test or instrument system.

"We are firmly resolute in supporting the global response to the COVID-19 pandemic by manufacturing independent quality solutions helping diagnostic companies and laboratories get to optimal test performance as quickly as possible," said Malcolm Bell, CEO and founder of Technopath. "With some clinical labs processing up to 500,000 coronavirus antibody tests per month, the company is laser-focused on assuring the quality of patient testing, and we believe our third-party QC solutions will reduce potential errors allowing laboratories to release patient results with confidence."

To date, the Foundation for Innovative New Diagnostics (FIND) has identified 280 antibody tests (immunoassays) in development or on the market. In the US alone, the FDA has granted 12 antibody test authorizations, including Abbott, Roche, Ortho Clinical Diagnostics, Cellex, Chembio Diagnostic Systems, the Mount Sinai Health System, Autobio and DiaSorin.

"With antibody testing accelerating across nations, clinical laboratories should be demanding data on validation studies, sensitivity and specificity, and conducting those studies in their labs," said James O. Westgard, PhD, longtime leader in clinical laboratory quality-control and founder of Westgard QC. "Quality-control is one of the most critical aspects of laboratory testing, and laboratories need to be adding third-party controls to their methods as soon as possible."

The Importance of Independent Quality Controls

Quality Control material may be provided by the instrument manufacturer or by an independent control manufacturer. The control materials provided by the manufacturer of the instrument or reagents are often referred to as "in kit" controls. Third party controls are manufactured independently of the test system calibrators and reagents.

Often times a laboratory using an instrument manufacturer or in-kit control may receive a different control lot with each new reagent lot. This does not provide the laboratory with the benefits of long-term QC monitoring.

Third party controls with a longer shelf life allow use of the same control lot over multiple changes in reagents and calibrators, giving the laboratory the ability to detect shifts that may occur with new reagents or calibrators.

About Multichem COVID-19 (IgG, IgM and Neg) Solutions

These solutions are 3rd party quality control products that help provide an independent assessment of a diagnostic device or method for COVID-19 antibody testing. These controls are manufactured based on a human base matrix that helps provide a product analogous to a patient sample.

Tags : #Technopath #Antibody #QualityControl #Covid19

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026
Fatty Liver Disease: Connecting Metabolic Health With Liver CareNovember 12, 2026
Chronic Kidney Disease: Understanding Risk Assessment and Early MonitoringNovember 12, 2026
Advanced OCTA Diagnostics in Age-Related Macular Degeneration (AMD)November 11, 2026
Advanced Diagnostics in Age-Related Macular Degeneration (AMD): Optical Coherence Tomography Angiography (OCTA)November 11, 2026
PCOS Care in India: Understanding Diagnosis and Long-Term MonitoringNovember 11, 2026
Thyroid Health: Making Sense of Testing and Follow-UpNovember 11, 2026
Advanced Navigation Systems in Neurosurgery: Precision TechNovember 11, 2026
Ambient Computing in Healthcare: India's Invisible Tech RevolutionNovember 11, 2026
World Diabetes Day 2026, ‘Early Action on Diabetes,’November 10, 2026
Gulf Medical University Celebrates 28 Years: Born in Thumbay, Built at GMUNovember 10, 2026